Ask about this productRelated genes to: PRPF6 Blocking Peptide
- Gene:
- PRPF6 NIH gene
- Name:
- pre-mRNA processing factor 6
- Previous symbol:
- C20orf14
- Synonyms:
- TOM, bB152O15.1, ANT-1, U5-102K, Prp6, hPrp6, SNRNP102, RP60
- Chromosome:
- 20q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-21
- Date modifiied:
- 2015-08-25
Related products to: PRPF6 Blocking Peptide
Related articles to: PRPF6 Blocking Peptide
- Convergent evolution offers a unique lens through which to explore the molecular underpinnings of significant phenotypic transformations. Similar selective pressures likely drove the evolution of analogous milk traits in sheep and goats. Consequently, the current study aimed to identify common selection signals for milk traits across dairy and non-dairy breeds of sheep and goats worldwide. - Source: PubMed
Publication date: 2026/02/06
Akhatayeva ZhanerkeShi YilongDossybayev KairatMalmakov NurlanCheng HairongBaatar NarantuyaYang JiLi MenghuaLin KejianXu Songsong - This report identifies the first N-terminal variant (c.514C>T) as a cause of autosomal dominant Retinitis Pigmentosa. This novel variant is associated with progressive peripheral vision loss but notably preserved central visual acuity, suggesting a distinct phenotypic expression compared to C-terminal variants. - Source: PubMed
Publication date: 2026/01/22
Li NaDang Yalong - Although metabolic reprogramming in colorectal cancer (CRC) has been studied, the changes in metabolic pathways and cellular communication from a healthy colon to precancerous adenoma and CRC remain poorly understood. - Source: PubMed
Publication date: 2025/10/27
Hu HuiWu JianhongLu Yanjun - As a key N-methyladenosine (mA) reader, YTH domain-containing family protein 1 (YTHDF1) promotes protein synthesis by recognizing mA-modified mRNA, and its abnormal expression is closely related to breast cancer (BC) progression. To date, the scarce reported YTHDF1 inhibitors suffer from poor selectivity and limited potency, primarily due to the high homology of the YTH domain within the YTHDF family, which poses significant challenges for the discovery of subtype-selective inhibitors. Here, we report SKLB-Y13, the first small-molecule inhibitor achieving exclusive targeting of the YTHDF1 mA-binding pocket (IC = 0.76 µM), via structural optimization of a novel 4,5,6,7-tetrahydrothieno[2,3-c]pyridine scaffold. Uniquely, SKLB-Y13 interacts with YTHDF1-specific residues Tyr397 and Trp470, as confirmed by site-directed mutagenesis, and demonstrates improved selectivity for YTHDF1 over YTH family proteins. Cellular and in vivo studies reveal that SKLB-Y13 disrupts YTHDF1-PRPF6 mRNA interaction in an mA-dependent manner, thereby impairing the translation of PRPF6 and inhibiting BC proliferation while promoting apoptosis. Chemical proteomics profiling confirms its good target specificity, while pharmacokinetic analysis shows favorable in vivo properties. This study introduces the first selective YTHDF1 inhibitor, serving as a novel chemical probe to elucidate mA-dependent oncogenesis and a promising starting point for developing precision therapies against YTHDF1-overexpressing BC. - Source: PubMed
Publication date: 2025/08/19
Wu YongyaFeng GuotaiShuai WenYang XiaoPan XiaoliZhu ChunyanWang AoxueSun QiuWang GuanOuyang Liang - As members of the nuclear receptor (NR) family of transcription factors, peroxisome proliferator-activated receptors (PPARs) regulate essential cellular processes, including lipid metabolism, glucose uptake, cell proliferation, and programmed cell death through ligand-mediated activation. Within the PPAR subfamilies, PPAR-γ (PPARG) is crucial to the development of fat cells, sensitivity to insulin, apoptosis, and metastasis. Furthermore, it demonstrates properties that counteract fibrosis and inflammation, thus establishing itself as a notable target for therapeutic interventions against conditions such as type 2 diabetes and cancer. PPARG is reported to be a promising target for patients diagnosed with colorectal cancer (CRC). Globally, colorectal cancer ranks as the third most prevalent malignancy and is responsible for approximately 10% of all cancer mortalities, and PPARG is significantly expressed in 70% of the sporadic CRC. In individuals with CRC, the precise function of PPARG remains not entirely comprehended and elucidation of the PPARG transcriptional regulation in CRC seems promising. - Source: PubMed
Publication date: 2025/06/11
Saha PrithaRavanan PalaniyandiTalwar Priti